|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Concert Pharmaceuticals, Inc. Announces Issuance of U.S. Patent for Its Lead Drug Candidate CTP-499
10/22/2012 9:17:29 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has been granted U.S. Patent No. 8,263,601 which covers CTP-499, the company’s lead drug candidate in development for the treatment of diabetic nephropathy, a form of chronic kidney disease (CKD). This patent claims the composition of matter and pharmaceutical compositions of CTP-499, which is currently in Phase 2 clinical testing. “We are very pleased to obtain this patent for our lead clinical candidate. This follows patent protection we recently received for several of our priority programs,” said Robert Silverman, Senior Vice President and General Counsel. “We have now used our DCE Platform® to make a wide range of substantially differentiated agents which are covered by a worldwide patent estate that includes 26 issued U.S. patents.”
|
|
|
|
|
|
|
|
|
|
|